The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology was recently held in conjunction with the 18th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology on November 21-24, 2013 in San Francisco, CA. The meeting enjoyed record attendance of close to 2100 registrants from 46 different countries.
We congratulate meeting chair, Dr. Mitchel Berger, for composing a comprehensive program which highlighted cutting-edge laboratory and clinical research. Special thanks are also extended to the scientific planning committee which was comprised of members from each of the three leading neuro-oncology societies, including Koich Ichimura & Ryo Nishikawa (ASNO), Riccardo Soffietti & Michael Weller (EANO) and Susan Chang & Russell Pieper (SNO). The meeting provided an enthusiastic environment for the exchange of ideas among clinical and laboratory scientists involved in the research, diagnosis, care and treatment of patients with central nervous system tumors.
The Education Day on Thursday, November 21 was entitled From Drug Discovery to Clinic and reviewed the various aspects of clinical development of agents that range from preclinical testing, pharmacokinetic and pharmacodynamic considerations, first in man studies, and the challenges of phase 0-III clinical trials. Alternate concurrent sessions appraised the specific challenges of clinical design and specific pathways that are being evaluated in the preclinical arena. Also featured was a Quality of Life Session with modules focused on Palliative Care, Symptom Management, and Pediatric Quality of Life.
WFNO Quadrennial and SNO Annual Meeting
The meeting built on the traditional SNO format and presented top-scoring abstracts and meet-the-expert sessions. The Scientific Meeting began Friday, November 22 with sunrise sessions followed by the start of the first general session. The four Sunrise Sessions were on the following topics: 1) Maximal Safe Resection of Glioma - Current Techniques; 2) Pediatric Genomics Update; 3) Innovative QOL Programs in the Clinic Setting; 4) Metabolic Imaging. After the sunrise sessions, the first plenary session started with an official meeting welcome by Dr. Mitchel Berger followed the Victor Levin Lecture by Monika Hegi and Roger Stupp. Dr. Kenneth Aldape then delivered his Presidential Address followed by the EANO Keynote Address by Stefan Pfister, MD, PhD, entitled Translating next generation diagnostics into next generation treatment.
A Young Investigators Luncheon Roundtable was held at noon on Friday at which trainees and early phase independent investigators participated in informal discussions with senior investigators at roundtables organized into a variety of different areas. Lunch was followed by afternoon concurrent sessions including 1) Pathology and Genomic and 2) Adult Clinical Sciences. The next set of concurrent sessions included 1) Angiogenesis and Invasion and 2) Pediatric Clinical Sciences. Friday evening, a special “Townhall Meeting” reviewed the results of the recent international randomized phase III trials evaluating the use of antiangiogenic strategies for newly diagnosed and recurrent glioblastoma session.
Saturday Sunrise Sessions featured the following topics: Session 1, WHO Classification of Tumors – Update; Session 2, Overview of GWAS and Potential for International Collaboration; Session 3, Immunological Strategies in Neuro-Oncology; Session 4, Assymetric Cell Division- Avenues for Research and Clinical Applications; Session 5, Joint AAN Session: Controversies in Neuro-Oncology. After the sessions a mini-symposium on Low Grade Gliomas was held and trailed by the ASNO Keynote Address by Do-Hyun Nam, MD, PhD, entitled Personalized targeted therapeutics based on the genomic characterized patient derived model (Avatar) system. Up next, award winning abstracts were presented and they were followed by the SNO Keynote address by Frank McCormick, PhD, entitled New Ways of Targeting Ras.
The first of its kind mid-level faculty networking luncheon was held at noon on Saturday with the intent of forming a horizontal mentoring group. After lunch we witnessed the first set of Saturday afternoon concurrent session: 1) Cell Biology and Signaling, 2) Molecular Epidemiology and Biomarkers. The second set of concurrent sessions included 1) Pediatric Basic and Translational Research and 2) Neurocognitive Outcomes and Quality of Life. A poster session was organized after the oral sessions concluded for the day. That evening, the SNO Gala Dinner, at San Francisco City Hall, was the social highlight of the meeting at allowed us to recognize the important service of those who make the meeting possible.
The Sunday, November 24th Sunrise Sessions included 1) Brain Metastases; 2) Minimizing Side Effects From Radiation; 3) Tumor Associated Epilepsy; 4) Microglia. The sunrise sessions were followed by concurrent meetings on Metabolic Pathways/Stem Cells and Imaging and RANO Update. The last concurrent sessions were 1) Preclinical Therapeutics and 2) Biologic/Immunologic Therapies followed by the meeting’s adjournment.
We look forward to seeing you at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology which will be held November 13-16, 2014, in Miami, Florida! Details as they become available will be posted on this website.